Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Olema Pharmaceuticals is a clinical-stage oncology company developing OP-1250, an oral selective estrogen receptor degrader (SERD) targeting endocrine-resistant breast cancer. The company's lead asset is in Phase 3 trials (OPERA-01) for ER+/HER2- metastatic breast cancer, competing against AstraZeneca's Orserdu and Sanofi's elacestrant. With no revenue and $1.8B market cap following 349% annual return, the stock trades on clinical trial readouts and regulatory milestone expectations.
Olema operates a binary outcome model typical of clinical-stage biotechs: invest capital in R&D to advance OP-1250 through FDA approval, then monetize via direct commercialization in oncology specialty channels or partnership deals. The oral SERD market addresses limitations of injectable competitors (Faslodex) with estimated $3-5B peak sales potential in ER+ breast cancer. Pricing power derives from differentiated efficacy/safety profile versus existing SERDs and limited competition in oral formulations. Company burns approximately $100M annually on clinical trials and will require either partnership capital or equity raises to fund commercialization infrastructure.
Phase 3 OPERA-01 trial interim analysis and topline data readouts (primary endpoint: progression-free survival vs comparator)
FDA regulatory interactions including Breakthrough Therapy designation decisions and NDA filing timelines
Clinical data presentations at ASCO, ESMO, and San Antonio Breast Cancer Symposium showing OP-1250 efficacy vs Orserdu/elacestrant
Partnership announcements for ex-US commercialization rights or combination therapy collaborations
Equity financing announcements and cash runway updates given $100M+ annual burn rate
Single-asset dependency: OP-1250 represents 100% of company value with no diversified pipeline, creating binary Phase 3 trial outcome risk
Competitive intensity in oral SERD market with AstraZeneca (Orserdu approved 2023), Sanofi (elacestrant), and Eli Lilly programs potentially establishing efficacy benchmarks before OPERA-01 readout
Regulatory pathway uncertainty as FDA standards for ER+ breast cancer evolve, particularly regarding comparator arm selection and progression-free survival vs overall survival endpoints
AstraZeneca's Orserdu first-mover advantage in oral SERD market with 2+ year head start on commercial infrastructure and physician adoption
Combination therapy strategies from larger oncology players (Pfizer, Novartis) pairing CDK4/6 inhibitors with next-gen endocrine agents could limit OP-1250 monotherapy market
Biosimilar competition to existing standards of care (fulvestrant) reducing overall SERD pricing umbrella by 2027-2028 launch window
Cash burn of $100M+ annually requires equity financing within 24-30 months absent partnership, creating dilution risk for current shareholders
Pre-revenue valuation of $1.8B implies Phase 3 success already partially priced in, leaving asymmetric downside if trial fails or shows non-differentiated efficacy
Negative 42.5% ROA reflects ongoing cash consumption with no near-term path to profitability until 2028+ commercial launch
low - Clinical trial timelines and FDA approval processes are largely insulated from GDP fluctuations. However, financing environment affects ability to raise capital for trials and commercialization. Oncology drug demand is non-discretionary and recession-resistant, though payer reimbursement negotiations can tighten during economic stress.
High sensitivity through valuation multiple compression rather than operational impact. Rising rates increase discount rates applied to distant cash flows (2028+ revenue), disproportionately affecting pre-revenue biotechs trading on NPV of pipeline. 10-year Treasury moves directly impact biotech sector multiples. Additionally, higher rates increase cost of future equity raises needed to fund $200M+ commercialization investment. Fed policy shifts can trigger 20-40% sector-wide biotech volatility.
Minimal direct credit exposure with 0.01 debt/equity ratio and $800M+ cash position. Company funds operations through equity markets rather than debt. However, broader credit market stress affects biotech IPO/follow-on windows and partnership deal structures. High-yield spread widening typically correlates with reduced risk appetite for clinical-stage assets.
growth/momentum - Attracts high-risk biotech specialists and event-driven funds focused on binary clinical catalysts. The 349% one-year return and 165% three-month surge indicates momentum-driven trading around trial milestones. Institutional ownership likely concentrated in healthcare-focused hedge funds and biotech ETFs rather than broad index funds. Not suitable for income or value investors given no revenue, negative cash flow, and valuation based entirely on discounted future earnings 3-5 years out.
high - Clinical-stage single-asset biotechs exhibit extreme volatility around data readouts, with 30-50% single-day moves common on trial results. Recent 310% six-month return demonstrates momentum volatility. Beta likely exceeds 2.0 relative to broader market. Stock trades on binary outcomes rather than incremental fundamentals, creating option-like payoff structure inappropriate for risk-averse portfolios.
